Home Bancorp, Inc. (HBCP) At $42.19 Forms Top; Mei Pharma (MEIP) SI Decreased By 39.89%

Home Bancorp, Inc. (HBCP) formed multiple top with $44.30 target or 5.00% above today’s $42.19 share price. Home Bancorp, Inc. (HBCP) has $314.14 million valuation. The stock increased 0.21% or $0.09 during the last trading session, reaching $42.19. About 12,765 shares traded. Home Bancorp, Inc. (NASDAQ:HBCP) has risen 24.80% since January 9, 2017 and is uptrending. It has outperformed by 8.10% the S&P500.

Mei Pharma Incorporated (NASDAQ:MEIP) had a decrease of 39.89% in short interest. MEIP’s SI was 66,600 shares in January as released by FINRA. Its down 39.89% from 110,800 shares previously. With 133,300 avg volume, 1 days are for Mei Pharma Incorporated (NASDAQ:MEIP)’s short sellers to cover MEIP’s short positions. The SI to Mei Pharma Incorporated’s float is 0.2%. The stock increased 0.92% or $0.02 during the last trading session, reaching $2.2. About 127,761 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 20.90% since January 9, 2017 and is uptrending. It has outperformed by 4.20% the S&P500.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $81.29 million. The companyÂ’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) earned “Buy” rating by Oppenheimer on Monday, June 26. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) earned “Hold” rating by Stifel Nicolaus on Wednesday, September 6. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) on Wednesday, August 2 with “Buy” rating. On Wednesday, June 14 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Oppenheimer on Wednesday, May 31 with “Buy”. As per Friday, September 4, the company rating was maintained by Wedbush.

Among 2 analysts covering Home Bancorp (NASDAQ:HBCP), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Home Bancorp had 4 analyst reports since August 13, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Wednesday, July 26 by Raymond James. The firm has “Outperform” rating by Raymond James given on Wednesday, September 30. The firm has “Buy” rating given on Thursday, August 13 by Zacks. Sandler O’Neill maintained it with “Hold” rating and $46 target in Wednesday, October 18 report.

Analysts await Home Bancorp, Inc. (NASDAQ:HBCP) to report earnings on January, 23. They expect $0.63 earnings per share, up 5.00% or $0.03 from last year’s $0.6 per share. HBCP’s profit will be $4.69 million for 16.74 P/E if the $0.63 EPS becomes a reality. After $0.59 actual earnings per share reported by Home Bancorp, Inc. for the previous quarter, Wall Street now forecasts 6.78% EPS growth.